PMID- 35993999
OWN - NLM
STAT- MEDLINE
DCOM- 20220907
LR  - 20220907
IS  - 1747-4132 (Electronic)
IS  - 1747-4124 (Linking)
VI  - 16
IP  - 8
DP  - 2022 Aug
TI  - Analysis of the impact on efficacy of lubiprostone dose reduction to manage 
      adverse events in the treatment of chronic constipation in Japan.
PG  - 809-817
LID - 10.1080/17474124.2022.2114455 [doi]
AB  - OBJECTIVE: To compare outcomes between two doses of lubiprostone in patients with 
      chronic constipation (CC), to assess whether dose reduction affects efficacy. 
      METHODS: This open-label exploratory study involved 146 patients with CC treated 
      initially with lubiprostone 24 mcg twice daily for a planned duration of 4 weeks. 
      Patients who experienced adverse events (AEs) had their dose reduced to 12 mcg 
      twice daily (for 4 weeks). RESULTS: Lubiprostone dose was unchanged in 104 
      patients and reduced due to AEs in 42 patients. Significant differences in the 
      mean number of bowel movements per week favored the dose-reduced group at Week 1 
      and end of follow-up. No between-group differences were observed over time for 
      mean number of days per week with bowel movements or mean Bristol Stool Form 
      Scale scores. Symptoms of abdominal bloating, strained defecation, and sensation 
      of incomplete evacuation improved in both groups. Before dose reduction, nausea 
      was reported by 64.3% and diarrhea by 45.2% of patients in the dose-reduced 
      group; after dose reduction, no patients reported nausea and one patient reported 
      diarrhea. CONCLUSION: Dose reduction of lubiprostone reduced the incidence of 
      AEs, with no compromise to efficacy, and may be a suitable approach for patients 
      who develop AEs during treatment.
FAU - Ohbayashi, Hiroyuki
AU  - Ohbayashi H
AD  - Department of Allergy and Respiratory Medicine, Tohno-Chuo Clinic, Mizunami, 
      Japan.
FAU - Sato, Yasuo
AU  - Sato Y
AD  - Department of Gastroenterology, Sato Clinic, Shibuya- ku, Tokyo, Japan.
FAU - Kiuchi, Mari
AU  - Kiuchi M
AD  - Department of Internal Medicine, Kanauchi Medical Clinic, Shinjuku- ku, Tokyo, 
      Japan.
FAU - Nagazumi, Atsushi
AU  - Nagazumi A
AD  - Department of Internal Medicine, Kanauchi Medical Clinic, Shinjuku- ku, Tokyo, 
      Japan.
FAU - Kanzo, Takumi
AU  - Kanzo T
AD  - Medical Affairs, Mylan EPD G.K, Tokyo, Japan.
FAU - Kimura, Takazumi
AU  - Kimura T
AD  - Department of Gastroenterology, Kimuranaika-ichonaika, Yokohama, Kanagawa, Japan.
LA  - eng
PT  - Journal Article
DEP - 20220829
PL  - England
TA  - Expert Rev Gastroenterol Hepatol
JT  - Expert review of gastroenterology & hepatology
JID - 101278199
RN  - 7662KG2R6K (Lubiprostone)
RN  - F5TD010360 (Alprostadil)
SB  - IM
MH  - *Alprostadil/adverse effects
MH  - Constipation/diagnosis/drug therapy
MH  - Diarrhea/drug therapy
MH  - Double-Blind Method
MH  - *Drug Tapering
MH  - Humans
MH  - Japan
MH  - Lubiprostone/adverse effects
MH  - Nausea/chemically induced
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Lubiprostone
OT  - adverse events
OT  - chronic constipation
OT  - dose reduction
OT  - efficacy
EDAT- 2022/08/23 06:00
MHDA- 2022/09/08 06:00
CRDT- 2022/08/22 10:42
PHST- 2022/08/23 06:00 [pubmed]
PHST- 2022/09/08 06:00 [medline]
PHST- 2022/08/22 10:42 [entrez]
AID - 10.1080/17474124.2022.2114455 [doi]
PST - ppublish
SO  - Expert Rev Gastroenterol Hepatol. 2022 Aug;16(8):809-817. doi: 
      10.1080/17474124.2022.2114455. Epub 2022 Aug 29.